The majority of patients with GA want treatment to preserve their vision for longer³

People-shaped figures representing ~14% of GA patient population

In a claims analysis of newly diagnosed patients with GA,

~14%
of patients are being treated⁵*

People-shaped figures representing 84% of GA patient population

Yet in a survey of people with self-reported GA,

84%
said they would try a treatment to slow their GA and preserve their vision for longer^3†

GA requires a different mindset

It's about taking action now, so you can protect healthy retinal cells which may preserve vision as long as possible^1,2

My goal as a physician is to preserve that vision for as long as I can, and I think it’s crucial to intervene early.”

– Dr. Arshad M. Khanani, Vitreoretinal Surgeon

I want to maintain my eyesight for as long as possible, and I felt a real sense of urgency to find a treatment that may help that.”

– Ken, real GA patient

Image of Dr. Arshad Khanani with Ken, a real GA patient

Step into the role of protector today

When evaluating GA patients for treatment

Prioritize those at risk for accelerated progression¹

The sooner you act, the more you may preserve for longer.^1,2 See below for risk factors associated with faster progression of GA:

Multifocal lesions often grow faster than unifocal lesions⁶

Extrafoveal lesions often progress faster than foveal lesions⁶

Image of bilateral GA progression comparison

Patients with bilateral GA often progress faster than those with unilateral GA^6,7

Hyperfluorescence on FAF imaging is often correlated with faster lesion progression⁶

Proactively protecting healthy retinal cells for longer is essential, especially in those at risk of faster progression. Patients appreciate this early management.^1,2 It resonates with them if you are doing everything you can.”

– Dr. David S. Chin Yee, Retina Specialist

Quotes reflect patient experience at the time of printing. Physicians featured have been compensated.

FAF=fundus autofluorescence; GA=geographic atrophy; OD=oculus dexter; OS=oculus sinister.

*Data from Symphony Health, AMD Claims (142,301 newly diagnosed GA patients) June 1, 2020, to July 31, 2025.⁵

^†Results from a telephone survey of 203 individuals with self-reported GA. Participants were compensated for their time, and the survey was sponsored by a pharmaceutical company.³

The majority of patients with GA want treatment to preserve their vision for longer3

GA requires a different mindset

Step into the role of protector today

Prioritize those at risk for accelerated progression1

The sooner you act, the more you may preserve for longer.1,2 See below for risk factors associated with faster progression of GA:

Proactively protecting healthy retinal cells for longer is essential, especially in those at risk of faster progression. Patients appreciate this early management.1,2 It resonates with them if you are doing everything you can.”

See efficacy & safety data

The majority of patients with GA want treatment to preserve their vision for longer³

Prioritize those at risk for accelerated progression¹

The sooner you act, the more you may preserve for longer.^1,2 See below for risk factors associated with faster progression of GA:

Proactively protecting healthy retinal cells for longer is essential, especially in those at risk of faster progression. Patients appreciate this early management.^1,2 It resonates with them if you are doing everything you can.”